Upgrade

PMGC Holdings Inc.

ELAB

Last
$3.06
Day
-1.6%
1y
-99.8%
5y
-100.0%
52w
-99.9%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1334d
EMA 21
4.05
EMA 50
6.69
EMA 200
7163.36
20d high
-43.8%
5y high
-100.0%
5y range
0th
Website · 32 employees · United States

Positions held

Your positions

ELAB isn't in your positions.

Add it to see shares, cost, and P&L here.

Score
-6
Hold
avoid
Signal
Sell
Target
$3.99
Stop
$2.40
Stop distance
21.6%
Target vs last
+30.4%

Fundamentals

Market cap$2.53MEnterprise value-$2.19MTrailing P/E—Forward P/E—
PEG—Price / book0.11Beta-0.27Dividend yield0.00%
Revenue growth—Earnings growth—Gross margin-20.5%Operating margin-2.9%
Profit margin0.0%ROE-105.2%ROA-33.0%Debt / equity0.85
Current ratio1.36Free cash flow-$4.13MAnalyst recommendationnoneMean target—
52w high$2,671.2052w low$2.59

Quarterly

2026-Q22026-Q12025-Q42025-Q32025-Q22025-Q1
Revenue$1.3M$0.7M$0.3M$0.3M$0.0M—
Op margin-292.2%-486.8%-792.7%-767.5%——
Net income-$2.9M-$5.0M-$3.0M-$2.6M-$0.6M—
Gross margin29.5%33.8%35.3%27.3%——
Gross profit$0.4M$0.2M$0.1M$0.1M$0.0M—
Operating income-$3.8M-$3.3M-$2.4M-$2.2M-$1.0M—
  • Revenue +92% vs prior quarter ($1.3M vs $0.7M).
  • Gross margin 29.5% (was 33.8% prior quarter).
  • Operating margin expanded to -292.2%.

Yearly (6y)

20252024202320222021
Revenue$0.6M$0.0M$0.0M$0.8M—
Op margin-1156.0%——-233.4%—
Net income-$7.7M-$6.2M-$4.3M-$1.8M—
Gross margin31.4%——58.4%—
Gross profit$0.2M$0.0M$1.1M$0.4M—
Operating income-$6.8M-$3.7M-$1.1M-$1.8M—
Headline scan

No flags

• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).

News

2026-10-08 · PMGC Holdings Inc. Announces DBA as NorthStrive Holdings, Inc., Trademark License Agreement, and Website Update

2026-10-01 · PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy

2026-09-29 · PMGC Unit Working With Charles River Laboratories for Muscle Health Probiotic Testing

2026-09-29 · NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs

2026-09-18 · PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings

2026-09-01 · NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications

2026-08-26 · PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio

2026-08-25 · PMGC Holdings Signs Orbit2Orbit Term Sheet for Microgravity Muscle Research

2026-08-25 · PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

2026-08-21 · NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

2026-08-19 · PMGC Holdings Inc. Announces Anticipated Reverse Stock Split

2026-08-14 · PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q2 2026 Results and Files Form 10-Q; Total Assets Reach $36.6 Million, Up 184% from Year-End 2025 and 290% Year-over-Year, as Quarterly Revenue Nearly Doubles Sequentially

ELAB · daily-26.6% over 13 sessions
Close EMA21 EMA50 EMA200
2.443.254.074.895.712026-092026-092026-092026-092026-102026-102026-10
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin
-$5M-$3M-$2M-$0M$1M-793%-379%35%2025-Q22025-Q32025-Q42026-Q12026-Q2